



(51) International Patent Classification:
A61K 38/20 (2006.01)

(21) International Application Number:
PCT/US2021/013456

(22) International Filing Date:
14 January 2021 (14.01.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/961,141 14 January 2020 (14.01.2020) US
63/136,599 12 January 2021 (12.01.2021) US

(71) Applicant: **SYNTHEKINE, INC.** [US/US]; 1505 O'Brien Drive, Suite D, Menlo Park, California 94025 (US).

(72) Inventors: **EMMERICH, Jan**; c/o Synthekine, Inc., 1505 O'Brien Drive, Suite D, Menlo Park, California 94025 (US). **KAUDER, Steve**; c/o Synthekine, Inc., 1505 O'Brien Drive, Suite D, Menlo Park, California 94025 (US). **MC-CAULEY, Scott Alan**; c/o Synthekine, Inc., 1505 O'Brien Drive, Suite D, Menlo Park, California 94025 (US). **OFT,**


Martin; c/o Synthekine, Inc., 1505 O'Brien Drive, Suite D, Menlo Park, California 94025 (US).

(74) Agent: **HINSCH, Matthew E.** et al.; Kilpatrick Townsend & Stockton LLP, Mailstop: IP Docketing - 22, 1100 Peachtree Street, Suite 2800, Atlanta, GA 30309 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: BIASED IL2 MUTEINS METHODS AND COMPOSITIONS



(57) Abstract: The present disclosures related to human interleukin-2 (hIL2) muteins, pharmaceutical formulations thereof, methods for preparing interleukin-2 muteins, recombinant vectors and cells comprising nucleic acids encoding IL2 muteins and methods for the treatment of human disease.

[Continued on next page]

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*